Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab and Bendamustine Combination (NB) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT03343652 is registered in ClinicalTrials.gov with St. Petersburg State Pavlov Medical University as lead sponsor.

NCT NCT03343652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03343652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab and Bendamustine Combination (NB) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Lead sponsor
St. Petersburg State Pavlov Medical University
Phase
Phase 1/2
Overall status
Completed
Start date
May 27, 2017
Completion date
March 27, 2020
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin's lymphoma